{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:08:07Z","timestamp":1789776487109,"version":"4.0.1"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cell therapy is a vital field in modern medicine. This review assesses its global clinical development landscape, approved products, and regional regulatory characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search and analysis of global clinical trial databases (e.g., https:\/\/clinicaltrials.gov\/ClinicalTrials.gov), regulatory agency announcements, and relevant literature up to October 2025 was conducted. Key data points regarding trial numbers, phases, therapy types, and approved products were extracted and analyzed descriptively by region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A cumulative total of 10,373 cell therapy clinical trials were identified worldwide, with primary distribution across the United States (3,563 trials), China (3,365 trials), and Europe (1,584 trials). Oncology (56.1%) and immune system diseases (9.3%) were the main research focuses. Immune cell therapy (5,167 trials) and stem cell therapy (4,796 trials) received comparable attention, with CAR-T therapy (2,409 trials) being prominent within the former, and mesenchymal stem cells (MSCs, 1,904 trials) and hematopoietic stem cells (HSCs, 1,550 trials) dominating the latter. Since 2016, China has led in the number of clinical trials, particularly in CAR-T research. Europe had a significantly higher proportion of Phase III trials compared to China and the US. The US led in the approval of HSC-based drugs. Approved immune cell drugs are predominantly CAR-T products for hematological malignancies, originating mainly from the US and China. Approved stem cell drugs are primarily HSC and MSC products, authorized in the US, Japan, South Korea, and China, covering indications such as graft-versus-host disease. Other somatic cell therapies are established for skin repair, bone disorders, and ophthalmology, with South Korea leading in skin-related products.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings reveal distinct regional strengths and strategic emphases in cell therapy development. The observed patterns are significantly influenced by heterogeneous regulatory frameworks across regions. The global industry is advancing the translation of cell therapy from cutting-edge technology to accessible clinical application through the synergy of scientific innovation and evolving regulatory pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1715984","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:29:04Z","timestamp":1770622144000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Global Panoramic analysis of clinical research in cell therapy: clinical trial landscape, marketed products, and regulatory trends"],"prefix":"10.3389","volume":"17","author":[{"given":"Mengmeng","family":"Wang","sequence":"first","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiange","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Liu","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanwan","family":"Xiang","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewen","family":"Xie","sequence":"additional","affiliation":[{"name":"Fu Foundation School of Engineering and Applied Science, Columbia University","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Hu","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengling","family":"Fang","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meimei","family":"Chen","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancai","family":"Wu","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.jtct.2025.01.065","article-title":"Real world experience in the United States following FDA approval of cultured thymus tissue implantation in congenital athymia patients at duke university","volume":"31","author":"Alqahtani","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2210046","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae(tisagenlecleucel)\u2013an overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum. Vaccines and Immunotherapeutics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1080\/13696998.2024.2354150","article-title":"Comparative analysis of tabelecleucel and current treatment in patients with epstein-barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant","volume":"27","author":"Barlev","year":"2024","journal-title":"J. Med. Econ."},{"key":"B6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/ksa.12248","article-title":"Hydrogel\u2010based and spheroid\u2010based autologous chondrocyte implantation of the knee show similar 2\u2010year functional outcomes: an analysis based on the German cartilage registry (KnorpelRegister DGOU)","volume":"32","author":"Bumberger","year":"2024","journal-title":"Knee Surg. Sports Traumatol. Arthrosc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-020-01783-8","article-title":"Ex vivo cultivated oral mucosal epithelial cell transplantation for limbal stem cell deficiency: a review","volume":"11","author":"Cabral","year":"2020","journal-title":"Stem Cell Research and Therapy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12916-024-03637-z","article-title":"Post-marketing surveillance framework of cell and gene therapy products in the European Union, the United States, Japan, South Korea and China: a comparative study","volume":"22","author":"Cai","year":"2024","journal-title":"BMC Medicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2474-11-103","article-title":"Gel-type autologous chondrocyte (Chondron\u2122) implantation for treatment of articular cartilage defects of the knee","volume":"11","author":"Choi","year":"2010","journal-title":"BMC Musculoskeletal Disorders"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1016\/S2352-3026(19)30202-9","article-title":"Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1\u20132 safety and feasibility study","volume":"7","author":"Cohen","year":"2020","journal-title":"Lancet Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/s0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3390\/ph16091334","article-title":"Mesenchymal stem cell therapies approved by regulatory agencies around the world","volume":"16","author":"Fern\u00e1ndez-Garza","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1016\/j.jhep.2015.02.040","article-title":"Cell therapy for liver disease: from liver transplantation to cell factory","volume":"62","author":"Forbes","year":"2015","journal-title":"J. Hepatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s43441-022-00480-3","article-title":"Regulatory pathways supporting expedited drug development and approval in ICH member countries","volume":"57","author":"Franco","year":"2023","journal-title":"Ther. Innovation and Regul. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1182\/blood-2023-184373","article-title":"Three-year follow-up on efficacy and safety results from phase 1 lummicar study 1 of zevorcabtagene autoleucel in Chinese patients with relapsed or refractory multiple myeloma","volume":"142","author":"Fu","year":"2023","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa2405727","article-title":"Long-term effects of atidarsagene autotemcel for metachromatic leukodystrophy","volume":"392","author":"Fumagalli","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/1078-0432.CCR-18-3328","article-title":"First CAR to pass the road test: tisagenlecleucel's drive to FDA approval","volume":"25","author":"Geyer","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B22","article-title":"Mesenchymal stromal cells: basics, classification, and clinical applications","volume":"13","author":"Gottipamula","year":"2018","journal-title":"J. Stem Cells"},{"key":"B23","first-page":"1097","article-title":"Escal\u00f3n: a prospective randomized trial of corneal endothelial cell therapy in subjects with corneal edema","volume":"10","author":"Holland","year":"2022","journal-title":"Cornea"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.burns.2019.07.021","article-title":"An open-label, prospective, randomized, controlled, multicenter, phase 1b study of StrataGraft skin tissue versus autografting in patients with deep partial-thickness thermal burns","volume":"45","author":"Holmes","year":"2019","journal-title":"Burns"},{"key":"B25","doi-asserted-by":"publisher","first-page":"106565","DOI":"10.1016\/j.clineuro.2021.106565","article-title":"Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series","volume":"203","author":"Honmou","year":"2021","journal-title":"Clin. Neurology Neurosurg."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.1182\/blood-2023-181167","article-title":"Omidubicel-onlv for allogeneic transplantation (allo-HCT) in patients with hematologic malignancies: results of a multicenter open label expanded access program","volume":"142","author":"Horwitz","year":"2023","journal-title":"Blood"},{"key":"B27","first-page":"1","article-title":"Revakinagene taroretcel: first approval: SM hoy","author":"Hoy","year":"2025","journal-title":"Mol. Diagnosis and Ther."},{"key":"B28","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3389\/fphar.2019.00921","article-title":"Regulatory framework for advanced therapy medicinal products in Europe and United States","volume":"10","author":"Iglesias-L\u00f3pez","year":"2019","journal-title":"Front. Pharmacology"},{"key":"B29","article-title":"Cell therapy. Basel: Jain PharmaBiotech","author":"Jain","year":"2016"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-4588261\/v1","article-title":"Gradual treatment effect from mesenchymal stem cell on steroid-refractory aGVHD in patients receiving above 8 infusions and with gut involvement: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial","author":"Jiang","year":"2024"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1182\/blood-2023-174229","article-title":"Efficacy, safety, and health-related quality of life (hrqol) in patients with sickle cell disease (scd) who have received lovotibeglogene autotemcel (Lovo-Cel) gene therapy: up to 60 months of follow-up","volume":"142","author":"Kanter","year":"2023","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9834","DOI":"10.1038\/s41598-024-59798-7","article-title":"Comparative study on clinical outcomes in autologous chondrocyte implantation using three-dimensional cultured JACC\u00ae with collagen versus periosteum coverings","volume":"14","author":"Kato","year":"2024","journal-title":"Sci. Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.bbmt.2008.03.012","article-title":"Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease","volume":"15","author":"Kebriaei","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.clim.2007.07.014","article-title":"Phase I\/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma","volume":"125","author":"Kim","year":"2007","journal-title":"Clin. Immunology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"E1372","DOI":"10.1097\/BRS.0000000000001670","article-title":"Pseudarthrosis repair using autologous cultured osteoblasts in complex type-1 neurofibromatosis spinal deformity: a case report and review of the literature","volume":"41","author":"Kim","year":"2016","journal-title":"Spine"},{"key":"B36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10557-018-6804-z","article-title":"Improvement in left ventricular function with intracoronary mesenchymal stem cell therapy in a patient with anterior wall ST-segment elevation myocardial infarction","volume":"32","author":"Kim","year":"2018","journal-title":"Cardiovasc. Drugs Therapy"},{"key":"B37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bbmt.2013.11.001","article-title":"Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients","volume":"20","author":"Kurtzberg","year":"2014","journal-title":"Biol. Blood Marrow Transplantation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","article-title":"A phase 3, single-arm, prospective study of remestemcel-L, Ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/S0140-6736(24)01884-1","article-title":"Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype \u03b2-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial","volume":"404","author":"Kwiatkowski","year":"2024","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1016\/j.joca.2018.02.300","article-title":"Results of treatment of scaffold-free pellet-type autologous chondrocytes implantation (cartilifeTM) in patients with knee cartilage lesions. A multi-center, active-controlled, randomized trial","volume":"26","author":"Lee","year":"2018","journal-title":"Osteoarthr. Cartil."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1109873","DOI":"10.3389\/fpubh.2023.1109873","article-title":"Cell and gene therapy regulatory, pricing, and reimbursement framework: with a focus on South Korea and the EU","volume":"11","author":"Lee","year":"2023","journal-title":"Front. Public Health"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","article-title":"Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial","volume":"10","author":"Li","year":"2024","journal-title":"JAMA Oncology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2325967120973052","DOI":"10.1177\/2325967120973052","article-title":"Allogeneic umbilical cord blood\u2013derived mesenchymal stem cell implantation versus microfracture for large, full-thickness cartilage defects in older patients: a multicenter randomized clinical trial and extended 5-year clinical follow-up","volume":"9","author":"Lim","year":"2021","journal-title":"Orthop. Journal Sports Medicine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene autotemcel gene therapy for non\u2013\u03b20\/\u03b20 genotype \u03b2-thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1002\/lary.28453","article-title":"Autologous fibroblasts for vocal scars and age\u2010related atrophy: a randomized clinical trial","volume":"130","author":"Ma","year":"2020","journal-title":"Laryngoscope"},{"key":"B49","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","article-title":"Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein\u2013barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial","volume":"25","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1442-9071.2011.02609.x","article-title":"Long\u2010term effectiveness of autologous cultured limbal stem cell grafts in patients with limbal stem cell deficiency due to chemical burns","volume":"40","author":"Marchini","year":"2012","journal-title":"Clin. and Experimental Ophthalmology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","author":"Maude","year":"2016"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1200\/JCO-25-00765","article-title":"Long-term efficacy and safety of Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study","volume":"43","author":"Medina","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1001\/jamasurg.2024.4893","article-title":"Bioengineered human arteries for the repair of vascular injuries","volume":"160","author":"Moore","year":"2025","journal-title":"JAMA Surgery"},{"key":"B55","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10047-017-1007-0","article-title":"A case report of the first application of culture epithelial autograft (JACE\u00ae) for giant congenital melanocytic nevus after its approval in Japan","volume":"21","author":"Morimoto","year":"2018","journal-title":"J. Artif. Organs"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat. Medicine"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1148444","DOI":"10.3389\/fnagi.2023.1148444","article-title":"Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R\u00ae: lenzumestrocel) treatment in ALS: propensity-score-matched control, surveillance study","volume":"15","author":"Nam","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ophtha.2023.01.016","article-title":"Clinical trial of autologous cultivated limbal epithelial cell sheet transplantation for patients with limbal stem cell deficiency","volume":"130","author":"Oie","year":"2023","journal-title":"Ophthalmology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4252\/wjsc.v16.i3.257","article-title":"Long-term outcome of stem cell transplantation with and without anti-tumor necrotic factor therapy in perianal fistula with Crohn\u2019s disease","volume":"16","author":"Park","year":"2024","journal-title":"World J. Stem Cells"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2337\/db24-35-or","article-title":"35-OR: Lantidra, first FDA-approved cellular therapy to treat type 1 diabetes","volume":"73","author":"Rios","year":"2024","journal-title":"Diabetes"},{"key":"B62","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med. (NEJM)"},{"key":"B63","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-4181","article-title":"FDA approval summary: Idecabtagene vicleucel for the treatment of triple-class exposed, relapsed or refractory multiple myeloma","author":"Sharma","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/j.1524-4725.2012.02349.x","article-title":"A multicenter, double-blind, placebo-controlled trial of autologous fibroblast therapy for the treatment of nasolabial fold wrinkles","volume":"38","author":"Smith","year":"2012","journal-title":"Dermatol. Surgery"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1182\/blood-2021-150085","article-title":"Primary clinical response of relmacabtagene autoleucel in adults with relapsed\/refractory follicular lymphoma (r\/r FL) in China","volume":"138","author":"Song","year":"2021","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"10329","DOI":"10.1182\/blood-2022-162985","article-title":"Efficacy and safety of relmacabtagene autoleucel in adults with relapsed\/refractory follicular lymphoma in China","volume":"140","author":"Song","year":"2022","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s001250051636","article-title":"From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus","volume":"44","author":"Soria","year":"2001","journal-title":"Diabetologia"},{"key":"B68","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(25)00778-0","article-title":"Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial","author":"Tang","year":"2025","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nrm.2016.10","article-title":"Pluripotent stem cells progressing to the clinic","volume":"17","author":"Trounson","year":"2016","journal-title":"Nat. Reviews Mol. Cell Biology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/13696998.2025.2469460","article-title":"Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible","volume":"28","author":"Velez","year":"2025","journal-title":"J. Med. Econ."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2011.1759","article-title":"FDA grants approval for first cord blood product","volume":"306","author":"Voelker","year":"2011","journal-title":"JAMA"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. Journal Medicine"},{"key":"B73","doi-asserted-by":"publisher","first-page":"7200","DOI":"10.1182\/blood-2024-201125","article-title":"Efficacy and safety of inaticabtagene autoleucel in children with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia in China","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","article-title":"The emerging landscape of immune cell therapies","volume":"181","author":"Weber","year":"2020","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.1182\/blood-2022-164525","article-title":"Preliminary safety and efficacy of relmacabtagene autoleucel (Relma-cel) in adults with relapsed\/refractory mantle cell lymphoma (r\/r MCL) in China","volume":"140","author":"Ying","year":"2022","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s13770-024-00647-z","article-title":"Implantation of culture-expanded bone marrow derived mesenchymal stromal cells for treatment of osteonecrosis of the femoral head","volume":"21","author":"Yoon","year":"2024","journal-title":"Tissue Eng. Regen. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1177\/0363546517717679","article-title":"Clinical and radiological regeneration of large and deep osteochondral defects of the knee by bone augmentation combined with matrix-guided autologous chondrocyte transplantation","volume":"45","author":"Zellner","year":"2017","journal-title":"Am. J. Sports Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-019-1165-5","article-title":"Stem cells: past, present, and future","volume":"10","author":"Zakrzewski","year":"2019","journal-title":"Stem Cell Research and Therapy"},{"key":"B79","article-title":"HR001, a novel CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory non-hodgkin's lymphoma: primary results of a phase II study (HRAIN01-NHL01-II)[C]\/\/CANCER RESEARCH. 615 CHESTNUT ST, 17TH FLOOR","volume":"84","author":"Zhang","year":"2024","journal-title":"Phila. PA 19106-4404 U. S. A. AMER ASSOC CANCER Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.34172\/ijhpm.8543","article-title":"A new outcomes-based payment plan from a Chinese company to improve patient affordability of CAR-T product","volume":"13","author":"Zheng","year":"2024","journal-title":"Int. J. Health Policy Manag."},{"key":"B81","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41392-024-01770-y","article-title":"Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1715984\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:59:41Z","timestamp":1771927181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1715984\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":81,"alternative-id":["10.3389\/fphar.2026.1715984"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1715984","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"article-number":"1715984"}}